Quarterly Metrics: Quick and Current Ratios for Marinus Pharmaceuticals Inc (MRNS)

For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Marinus Pharmaceuticals Inc’s stock clocked out at $1.90, up 16.56% from its previous closing price of $1.63. In other words, the price has increased by $16.56 from its previous closing price. On the day, 2.97 million shares were traded. MRNS stock price reached its highest trading level at $1.97 during the session, while it also had its lowest trading level at $1.5643.

Ratios:

To gain a deeper understanding of MRNS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.15 and its Current Ratio is at 2.28.

Robert W. Baird Downgraded its Outperform to Neutral on April 16, 2024, whereas the target price for the stock was revised from $20 to $2.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 05 ’24 when Pfanstiel Steven sold 4,657 shares for $1.13 per share. The transaction valued at 5,262 led to the insider holds 79,773 shares of the business.

Shafer Christina sold 3,820 shares of MRNS for $4,355 on Aug 05 ’24. The CHIEF COMMERCIAL OFFICER now owns 67,406 shares after completing the transaction at $1.14 per share. On Aug 05 ’24, another insider, MANNING MARTHA E, who serves as the SVP, GEN. COUNSEL & CORP. SEC. of the company, sold 3,621 shares for $1.13 each. As a result, the insider received 4,092 and left with 60,263 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNS now has a Market Capitalization of 104659600 and an Enterprise Value of 135877680. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.46. Its current Enterprise Value per Revenue stands at 4.49 whereas that against EBITDA is -1.056.

Stock Price History:

Over the past 52 weeks, MRNS has reached a high of $11.26, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 37.49%, while the 200-Day Moving Average is calculated to be -61.64%.

Shares Statistics:

It appears that MRNS traded 659.82K shares on average per day over the past three months and 956470 shares per day over the past ten days. A total of 54.58M shares are outstanding, with a floating share count of 47.97M. Insiders hold about 12.92% of the company’s shares, while institutions hold 67.54% stake in the company. Shares short for MRNS as of 1724976000 were 2737774 with a Short Ratio of 4.15, compared to 1722384000 on 2506830. Therefore, it implies a Short% of Shares Outstanding of 2737774 and a Short% of Float of 4.99.

Most Popular